Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny
- PMID: 36863389
- DOI: 10.1016/S2468-1253(23)00041-9
Bringing dietary therapy for eosinophilic oesophagitis under scientific scrutiny
Conflict of interest statement
I declare participation on advisory boards for Regeneron/Sanofi, Dr Falk Pharma, GlaxoSmithKline, and Bristol Myers Squibb, and participation on a data safety monitoring board for AstraZeneca.
Comment on
-
One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial.Lancet Gastroenterol Hepatol. 2023 May;8(5):408-421. doi: 10.1016/S2468-1253(23)00012-2. Epub 2023 Feb 28. Lancet Gastroenterol Hepatol. 2023. PMID: 36863390 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Medical